CSPG4 and obstructive sleep apnea syndrome: Based on these results, and on the safety, immunogenicity and potential clinical benefit of a chimeric human/dog (HuDo)-CSPG4 DNA vaccine that we recently tested in the adjuvant setting in dogs affected by spontaneous CSPG4-positive oral melanoma [166], we are now also evaluating HuDo-CSPG4 DNA vaccination in OSA canine patients.